Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure (Q34206601)

31 July 2017

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure (English)

1 reference

31 July 2017

phase II clinical trial

0 references

9

Toni K Choueiri

1 reference

31 July 2017

Nizar M Tannir

1

1 reference

31 July 2017

Yu-Ning Wong

2

1 reference

31 July 2017

Christian K Kollmannsberger

3

1 reference

31 July 2017

Marc S Ernstoff

4

1 reference

31 July 2017

David J Perry

5

1 reference

31 July 2017

Leonard J Appleman

6

1 reference

31 July 2017

Edwin M Posadas

7

1 reference

31 July 2017

Daniel Cho

8

1 reference

31 July 2017

Andrew Coates

10

1 reference

31 July 2017

Neeraj Gupta

11

1 reference

31 July 2017

Rajendra Pradhan

12

1 reference

31 July 2017

Jiang Qian

13

1 reference

31 July 2017

Jihong Chen

14

1 reference

31 July 2017

Frank A Scappaticci

15

1 reference

31 July 2017

Justin L Ricker

16

1 reference

31 July 2017

Dawn M Carlson

17

1 reference

31 July 2017

M Dror Michaelson

18

1 reference

31 July 2017

10 November 2011

1 reference

European Journal of Cancer

31 July 2017

1 reference

31 July 2017

47

1 reference

31 July 2017

18

1 reference

31 July 2017

2706-2714

1 reference

Systemic therapy for advanced renal cell carcinoma

31 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Management of metastatic renal cell carcinoma: current trends

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Survival probabilities (the Kaplan-Meier method).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Targeting renal cell carcinoma.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Understanding the standardized uptake value, its methods, and implications for usage.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4167844

10.1016/J.EJCA.2011.09.002

28 October 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference

31 July 2017

1 reference